Cory Freedland, Ph.D., Venture Partner

Cory Freedland, Ph.D. is a Venture Partner at Samsara BioCapital, which he joined in October 2017. Prior to Samsara BioCapital, he was a Principal at Sofinnova Ventures, where he focused on biopharmaceutical investments. Prior to Sofinnova Ventures, Dr. Freedland was a Principal at Novo A/S. Before his transition to healthcare investing, he was a Vice President in the healthcare investment banking practice at Morgan Stanley. Prior to transitioning to life sciences finance, Dr. Freedland worked as a Research Scientist for Roche, focusing on preclinical drug discovery and novel target identification for psychiatric and neurodegenerative diseases. He previously served on the Board of Directors of Jiya Acquisition Corporation. Dr. Freedland received his Ph.D. in Pharmacology from the Wake Forest University School of Medicine, his M.B.A. from the Kellogg School of Management, and his B.A. in Psychology and Religious Studies from Connecticut College.